EUVIMEDEUVIMED entdecken
Crossref

Plasma Chemerin may predict Type-2 Diabetes Remission after Bariatric Surgery

Ángel Alfonso Garduño-Pérez, Jesús Montoya-Ramírez, Gustavo De La Peña-Sosa, Karen De La VegaMoreno, Dulce Cecilia Vázquez-Ramos, Andrea Ramírez-Coyotecatl, Eduardo Vera-Gómez, Alejandro Hernández-Patricio, Carlos Ramiro Zamora-Alemán, Silvia García, Juan Antonio Suárez-Cuenca

International Journal of Diabetes & Metabolic Disorders · 18.03.2026 · 11 (01) · 01-06

DOI: 10.33140/ijdmd.11.01.01 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Diabetes & Metabolic Disorders, online erschienen am 18.03.2026. Verfasst von Ángel Alfonso Garduño-Pérez und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bariatric surgery is an effective treatment for patients with severe obesity and type 2 diabetes mellitus (T2DM), leading to significant metabolic improvement and diabetes remission in a substantial proportion of cases. However, remission is not universal, and biological factors influencing postoperative metabolic response remain incompletely characterized. Adipokines such as chemerin and visfatin have been implicated in insulin resistance and adipose tissue inflammation and may contribute to heterogeneous outcomes after surgery.

Aim

To evaluate metabolic changes associated with T2DM remission after bariatric surgery and to assess the relationship between preoperative circulating adipokines and diabetes remission.

Methods

Prospective observational cohort study of 30 adults with T2DM and severe obesity undergoing bariatric surgery. Clinical, anthropometric, and biochemical variables were assessed at baseline and at 6 months postoperatively. Patients were classified according to complete T2DM remission status.

Results

At 6 months, 14 patients (46%) achieved complete T2DM remission. Remission was associated with significant reductions in fasting glucose and HbA1c, increased HDL-cholesterol, and reduced triglycerides. Higher preoperative chemerin levels were associated with lack of remission, while visfatin showed no significant association.

Conclusions

Elevated preoperative chemerin levels may identify patients at risk of persistent T2DM after bariatric surgery

Zitieren

APA

Garduño-Pérez, Á. A., Montoya-Ramírez, J., Peña-Sosa, G. D. L., VegaMoreno, K. D. L., Vázquez-Ramos, D. C., Ramírez-Coyotecatl, A., Vera-Gómez, E., Hernández-Patricio, A., Zamora-Alemán, C. R., García, S., & Suárez-Cuenca, J. A. (2026). Plasma Chemerin may predict Type-2 Diabetes Remission after Bariatric Surgery. International Journal of Diabetes & Metabolic Disorders, 11(01), 01-06. https://doi.org/10.33140/ijdmd.11.01.01

Vancouver

Garduño-Pérez ÁA, Montoya-Ramírez J, Peña-Sosa GDL, VegaMoreno KDL, Vázquez-Ramos DC, Ramírez-Coyotecatl A, et al. Plasma Chemerin may predict Type-2 Diabetes Remission after Bariatric Surgery. International Journal of Diabetes & Metabolic Disorders. 2026;11(01):01-06. doi:10.33140/ijdmd.11.01.01

BibTeX
@article{GarduoPrez2026,
  author = {Garduño-Pérez, Ángel Alfonso and Montoya-Ramírez, Jesús and Peña-Sosa, Gustavo De La and VegaMoreno, Karen De La and Vázquez-Ramos, Dulce Cecilia and Ramírez-Coyotecatl, Andrea and Vera-Gómez, Eduardo and Hernández-Patricio, Alejandro and Zamora-Alemán, Carlos Ramiro and García, Silvia and Suárez-Cuenca, Juan Antonio},
  title = {Plasma Chemerin may predict Type-2 Diabetes Remission after Bariatric Surgery},
  journal = {International Journal of Diabetes & Metabolic Disorders},
  year = {2026},
  volume = {11},
  number = {01},
  pages = {01--06},
  doi = {10.33140/ijdmd.11.01.01}
}
Kostenlos starten →